PROMISING NEW EPILEPSY DRUG DELIVERS 80% REDUCTION IN SEIZURES

Summary from the TLDR newsletter

Rapport Therapeutics' experimental compound, RAP-219, reduced seizures by an average of 77.8% in a Phase 2a study. Almost a quarter of participants remained seizure-free over the two-month treatment period. The study raises hopes for patients who suffer from seizures despite being on multiple medications. Rapport plans to meet with the US Food and Drug Administration and then launch two Phase 3 trials next year. It is also developing a long-acting injectable version to address medication adherence, a frequent challenge in epilepsy.